Genelux Corporation announced today that it has successfully concluded a productive Type D meeting with the U.S. Food and Drug Administration (FDA) regarding the approval pathway for Olvi-Vec in the treatment of platinum-resistant/refractory ovarian cancer (PRROC). The FDA indicated that data from the company's ongoing Phase 3 registrational trial could potentially support traditional approval without requiring an additional confirmatory study.
Olvi-Vec (olvimulogene nanivacirepvec), which has already received Fast Track designation from the FDA for PRROC, is currently being evaluated in the OnPrime/GOG-3076 Phase 3 registrational trial with progression-free survival (PFS) as the primary endpoint.
During the regulatory meeting, the FDA provided clear guidance on requirements for traditional approval. The agency stated that "an interim analysis of overall survival (OS) should be planned at the time of the primary PFS analysis. If a clinically meaningful PFS advantage is demonstrated in the absence of a decrement in OS, this could potentially support traditional approval."
"We appreciate the feedback from the FDA regarding our clinical strategy for OnPrime/GOG-3076 and the plan for submission of an eventual marketing application, which could avoid the need for conducting a separate confirmatory study if the clinically meaningful PFS advantage is demonstrated," stated Thomas Zindrick, President and CEO of Genelux.
The FDA further recommended that Genelux request a pre-Biologics License Application (BLA) meeting with topline safety and efficacy data following completion of the study to discuss next steps.
Trial Design and Patient Population
The OnPrime/GOG-3076 trial is a multi-center, randomized, open-label Phase 3 study evaluating the efficacy and safety of Olvi-Vec in combination with platinum-doublet plus bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with PRROC.
The trial targets patients who are platinum-resistant/refractory by standard definitions and have received a minimum of three prior lines of therapy. In the experimental arm, patients receive a single cycle (two doses) of Olvi-Vec administered intraperitoneally followed by a regimen of platinum-based doublet plus bevacizumab and maintenance therapy. The comparator arm receives single-agent chemotherapy with optional platinum, plus bevacizumab followed by maintenance therapy.
The study is designed to enroll sufficient patients to achieve 127 events, with progression-free survival as the primary endpoint and overall survival among the secondary endpoints. Notably, the trial addresses a broad and underserved population of ovarian cancer patients with no approved standard of care therapies, allowing enrollment regardless of tumor biomarkers, platinum-refractory status, or the number of prior treatment lines.
Zindrick emphasized the significance of this regulatory guidance: "The FDA's guidance regarding their expectations for the ongoing trial represents a significant milestone as we look forward to reporting topline safety and efficacy data in the first half of 2026. We remain committed to advancing a therapeutic option with the potential to provide a significant benefit for individuals living with PRROC, whose critical unmet need for innovative treatments is urgent."
About Olvi-Vec
Olvi-Vec is Genelux's most advanced product candidate, a proprietary, modified oncolytic vaccinia virus designed as an immunotherapy for multiple cancer types. The therapy has shown potential to infect and directly kill a wide range of tumor cell types while producing an anti-tumor immune response.
To date, Olvi-Vec has been administered to more than 150 patients across seven completed clinical trials, where it was generally well tolerated with data demonstrating clinical benefit. Beyond the PRROC indication, Olvi-Vec is being evaluated in two additional clinical studies focused on platinum resensitization:
-
VIRO-25: A U.S.-based multi-center, randomized, open-label Phase 2 trial evaluating Olvi-Vec with platinum-doublet plus immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer
-
Olvi-Vec-SCLC-202: A Phase 1b/2, open-label, China-based multicenter trial evaluating intravenously delivered Olvi-Vec combined with platinum and etoposide in platinum-relapsed or platinum-refractory extensive small cell lung cancer
Addressing an Unmet Medical Need
Platinum-resistant/refractory ovarian cancer represents a significant challenge in gynecologic oncology, with limited effective treatment options and poor outcomes. Patients typically experience disease progression within six months of platinum-based therapy or fail to respond altogether.
The OnPrime/GOG-3076 trial's inclusive enrollment criteria reflect the urgent need for new therapeutic approaches in this difficult-to-treat population. By potentially streamlining the approval pathway, the FDA's guidance could accelerate access to a novel treatment option for patients with few alternatives.
Genelux, a late-stage clinical biopharmaceutical company focused on developing next-generation oncolytic immunotherapies, has built its pipeline around its proprietary CHOICE™ platform. This platform has enabled the company to develop an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic candidates, including Olvi-Vec.
The company expects to report topline safety and efficacy data from the OnPrime/GOG-3076 trial in the first half of 2026.
